The early phase of cartilage degeneration was immunohistochemically examined in order to clarify the importance of autoimmune reaction against type II collagen in MRL/Mp- lpr/lpr (MRL/ l) mouse in an experimental model of rheumatoid arthritis (RA). Anti-type II collagen antibodies were detectable in 3-week-old mice and preceded the appearance of rheumatoid factors. Furthermore, mesenchymal cells and tartrate-resistant acid phosphatase-positive cells began to accumulate remarkably in the periphysis, a fibrochondro-osseous area in the bone marrow vicinity. The numbers of these cells increased with mice age, together with serum levels of anti-type II collagen antibodies. Immunostaining of the periphysis revealed expression of type II collagen, IgG, C3, Mac-3, MHC class II antigen Ia, and cathepsin-L. Osteoclast-like cells and macrophage infiltration into the lesion area were confirmed by transmission electron microscopy. The results indicate that cartilage degeneration in MRL/ l mouse may originate in the periphysis and progress via a pathway independent of synovial invasion.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00296-003-0336-x | DOI Listing |
Comput Biol Chem
December 2024
Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
The mesenchymal stem cell (MSC) secretome plays a pivotal role in shaping the tumor microenvironment, influencing both cancer progression and potential therapeutic outcomes. In this research, by using publicly available dataset GSE196312, we investigated the role of MSC secretome on breast cancer cell gene expression. Our results raveled differentially expressed genes, including the upregulation of Phosphatidylinositol-3,4,5-Trisphosphate Dependent Rac Exchange Factor 1 (PREX1), C-C Motif Chemokine Ligand 28 (CCL28), and downregulation of Collagen Type I Alpha 1 Chain (COL1A1), Collagen Type I Alpha 3 Chain (COL1A3), Collagen Type III Alpha 1 Chain (COL3A1), which contributing to extra cellular matrix (ECM) weakening and promoting cell migration.
View Article and Find Full Text PDFMar Biotechnol (NY)
January 2025
Burn Research Center, Iran University of Medical Sciences, Tehran, Iran.
Burn wounds are challenging to treat due to considerable tissue damage and fluid loss. Creating wound dressings from natural and biological materials makes it possible to treat wounds and promote rapid epithelialization to speed healing and restore skin function. As a result, the ability of a collagen scaffold (Col) made from rainbow trout (Oncorhynchus mykiss) and putative bioactive phytochemical components from a Sargassum glaucescens (S.
View Article and Find Full Text PDFCalcif Tissue Int
January 2025
Department of Endocrinology, Odense University Hospital, Odense, Denmark.
Osteogenesis imperfecta (OI) is a group of rare genetic disorders most commonly caused by reduced amount of biologically normal collagen type I, a structural component of the gastrointestinal tract and abdominal wall. The risk of gastrointestinal (GI) disease in individuals with OI is not well understood, despite GI complaints being frequently reported by the OI population. To investigate the risk of GI diseases in individuals with OI.
View Article and Find Full Text PDFCalcif Tissue Int
January 2025
Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan.
Osteogenesis imperfecta (OI) is an inheritable skeletal disorder characterized by bone fragility often caused by pathogenic variants in the COL1A1 gene. Current OI mouse models with a glycine substitution in Col1a1 exhibit excessive severity, thereby limiting long-term pathophysiological analysis and drug effect assessments. To address this limitation, we constructed a novel OI mouse model mimicking a patient with OI type III.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of North Dakota, Grand Forks, ND, USA.
Background: Alzheimer's disease (AD) is an age-related neurodegenerative disorder affecting nearly 50 million individuals worldwide. Besides aging, various comorbidities can increase the risk of AD, such as asthma. However, the molecular mechanism(s) underlying this asthma-associated AD exacerbation is unknown.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!